83. A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region as defined by any preceding claim.

84. The nucleic acid of claim 83 having a sequence comprising any one of SEQ ID NO:18, 20, 22, 24, 26, 32, 34, 36, or 38.

85. A host cell comprising a vector comprising the nucleic acid of claim 83 or 84.

86. A pharmaceutical composition comprising an antibody as defined by any of claims 1-82.

87. The pharmaceutical composition of claim 86, for use in treating a patient having or at risk of a Lewy body disease, in reducing Lewy body formation in a patient having or at risk of a Lewy body disease, or of inhibiting synuclein aggregation or clearing Lewy bodies or synuclein aggregates in a patient having or at risk of a Lewy body disease.

~~87~~88. Use of an antibody as defined by any of claims 1-82, in the preparation of a medicament for ~~A method of~~ treating a patient having or at risk of a Lewy body disease~~, comprising administering to the patient an effective regime of an antibody as defined by any of claims 1-82~~.

~~88~~89. Use of an antibody as defined by any of claims 1-82, in the preparation of a medicament for ~~A method of~~ reducing Lewy body formation in a patient having or at risk of a Lewy body disease~~, comprising administering to the patient an effective amount of an antibody as defined by any of claims 1-82~~.

~~89~~90. Use of an antibody as defined by any of claims 1-82, in the preparation of a medicament for ~~A method of~~ inhibiting synuclein aggregation or clearing Lewy bodies or synuclein aggregates in a patient having or at risk of a Lewy body disease~~, comprising administering to the patient an effective amount of an antibody as defined by any of claims 1-82~~.

~~90~~91. A method of detecting Lewy bodies in a patient having or at risk of a Lewy body disease, comprising administering to the patient an effective amount of an antibody as defined by any of

claims 1-82, wherein the antibody binds to Lewy bodies; and detecting bound antibody in the patient.

~~91~~92. The method of claim ~~90~~91, wherein the antibody is labeled.

~~92~~93. The method of any of claims ~~87-91~~88-92, wherein the disease is Parkinson's disease.

~~93~~94. A method of producing an antibody, comprising culturing cells transformed with nucleic acids encoding the heavy and light chains of the antibody, so that the cell secrete the antibody; and purifying the antibody from cell culture media; wherein the antibody is defined by any of claims 1-82.

~~94~~95. A method of producing a cell line producing an antibody, comprising introducing a vector encoding heavy and light chains of an antibody and a selectable marker into cells; propagating the cells under conditions to select for cells having increased copy number of the vector; isolating single cells from the selected cell; and banking cells cloned from a single cell selected based on yield of antibody; wherein the antibody is an antibody as defined by any of claims 1-82.

~~95~~96. The method of claim ~~94~~95, further comprising propagating the cells under selective conditions and screening for cell lines naturally expressing and secreting at least 100 mg/L/106 cells/24 h.

~~96~~97. The method of any of claims ~~87-89~~88-90, wherein decline of cognitive function in the patient is inhibited.

~~97~~98. The method of any of claims ~~87-89~~88-90, wherein neuritic and/or axonal alpha synuclein aggregates are reduced.

~~98~~99. The method of any of claims ~~87-89~~88-90, wherein neuritic dystrophy in the patient is reduced.

~~99~~100. The method of any of claims ~~87-89~~88-90, wherein synaptic and/or dendritic density is preserved.

~~100~~101. The method of any of claims ~~87-89~~88-90, wherein the method preserves synaptophysin and/or MAP2 in the patient.